Ann Gregus

Chronic pain affects 30-40% of Americans, most of whom report that their pain is inadequately managed by current treatments. While opioids are effective for moderate to severe pain, they carry risks of addiction. Thus, our goal is to elucidate novel molecular mechanisms driving the transition from acute to chronic pain and to translate druggable targets into potential nonopioid therapeutics via a multi-omic approach using advanced mass spectrometry techniques, cell-based assays, and behavioral pharmacology to support early-stage drug discovery.